Compare AbbVie Inc (ABBV) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs General Motors Company — how do they compare? AbbVie Inc trades at $249.55 (market cap $438.19B), while General Motors Company trades at $89.2 (market cap $76.85B). The key difference: AbbVie Inc is far larger — about 5.7× General Motors Company's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | GM | |
|---|---|---|
Market Cap | $438.19B | $76.85B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $90.30 |
52-Week Low | $197.38 | $54.16 |
Enterprise Value | $502.45B | $179.83B |
Dividend Yield | 2.79% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
General Motors (GM) trades at $87.58, up 0.74% today, showing strong technical momentum with a bullish moving average signal and support at $87. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.57 beating expectations of $3.19. Recent developments include the renewal of GM's China joint venture with SAIC for 20 years and expansion of EV charging infrastructure with Pilot and EVgo.
GM presents a compelling investment case with analyst consensus price target of $108.82 (24% upside), strong institutional support (65% buy ratings), and improving cash flow trends. However, risks include declining profit margins (1.05% net margin in 2025), rising debt levels, and competitive pressures in the EV transition. The stock offers value with attractive valuation multiples (P/S 0.44, P/B 1.24) but requires monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
